Free Trial

Danaher Corporation $DHR is Montrusco Bolton Investments Inc.'s 6th Largest Position

Danaher logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Montrusco Bolton trimmed its stake in Danaher by 10.4% in Q4 to 1,444,568 shares, leaving DHR as its 6th largest position worth about $321.5M (≈0.20% of the company).
  • Danaher beat quarterly EPS ($2.06 vs. $1.94), reported revenue up 3.7% YoY, set FY2026 guidance of 8.350–8.550 EPS, and raised its quarterly dividend to $0.40 ($1.60 annualized, ~0.9% yield).
  • The company faces near-term headwinds including a ~$172.5M shareholder litigation settlement, rising short interest (~17.8%), and recent €3.0B senior notes issuance, while analyst targets and sentiment remain mixed.
  • Five stocks to consider instead of Danaher.

Montrusco Bolton Investments Inc. trimmed its stake in Danaher Corporation (NYSE:DHR - Free Report) by 10.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,444,568 shares of the conglomerate's stock after selling 166,963 shares during the period. Danaher accounts for approximately 4.0% of Montrusco Bolton Investments Inc.'s holdings, making the stock its 6th largest position. Montrusco Bolton Investments Inc. owned about 0.20% of Danaher worth $321,478,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the company. Wealth Science Advisors LLC bought a new position in Danaher in the 4th quarter worth $279,000. Quent Long Short Global Small Cap Fund LP bought a new position in shares of Danaher during the 4th quarter valued at about $655,000. Cornerstone Advisory LLC boosted its holdings in shares of Danaher by 19.3% during the 4th quarter. Cornerstone Advisory LLC now owns 1,913 shares of the conglomerate's stock valued at $438,000 after purchasing an additional 309 shares during the last quarter. Turtle Creek Wealth Advisors LLC lifted its holdings in shares of Danaher by 55.4% in the 4th quarter. Turtle Creek Wealth Advisors LLC now owns 3,715 shares of the conglomerate's stock valued at $850,000 after acquiring an additional 1,325 shares during the last quarter. Finally, waypoint wealth counsel lifted its holdings in shares of Danaher by 24.6% in the 4th quarter. waypoint wealth counsel now owns 2,829 shares of the conglomerate's stock valued at $648,000 after acquiring an additional 559 shares during the last quarter. Institutional investors own 79.05% of the company's stock.

Insider Buying and Selling

In other news, EVP Gregory M. Milosevich sold 1,320 shares of Danaher stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $208.01, for a total transaction of $274,573.20. Following the completion of the sale, the executive vice president directly owned 5,099 shares in the company, valued at approximately $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.80% of the stock is owned by company insiders.

Key Danaher News

Here are the key news stories impacting Danaher this week:

  • Positive Sentiment: Guggenheim reiterated a Buy rating on Danaher, supporting demand-side interest from institutional buyers. Guggenheim Reaffirms Buy
  • Positive Sentiment: An analyst price-target lift to $232 signals buy-side upside vs. current levels, which can support the stock if investors focus on medium-term earnings guidance. Price Target Raised to $232
  • Neutral Sentiment: Danaher priced ~€3.0 billion of euro-denominated senior notes across maturities (2028–2038). This raises liquidity for operations or M&A but increases long-term debt on the balance sheet. Senior Notes Offering
  • Neutral Sentiment: Coverage pieces question whether the recent share weakness makes DHR an attractive value play — useful for long-term investors but not an immediate catalyst. Valuation Article
  • Negative Sentiment: Danaher agreed to settle shareholder litigation tied to its post‑pandemic outlook for about $172.5M, a direct hit to cash and a reminder of past forecasting issues; that likely pressured sentiment. Settlement Report
  • Negative Sentiment: Short interest rose ~17.8% to 8.18M shares as of April 15 (≈1.3% of float; short-interest ratio ~2.5 days), indicating increased speculative/hedged bearish positioning that can amplify downward moves.
  • Negative Sentiment: Morgan Stanley trimmed its price target (from $270 to $255), and UBS issued a pessimistic forecast—both moves add analyst-driven downside pressure despite differing target levels. Morgan Stanley PT Cut UBS Forecast
  • Negative Sentiment: Analysts/commentary flag Danaher’s Masimo acquisition as adding long-term potential but creating near-term margin and integration pressure, a nearer-term risk to earnings momentum. Masimo Deal Commentary

Danaher Price Performance

NYSE DHR opened at $177.31 on Friday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.51 and a current ratio of 1.87. The firm's 50 day moving average price is $195.75 and its 200-day moving average price is $213.86. Danaher Corporation has a 52-week low of $175.00 and a 52-week high of $242.80. The company has a market cap of $125.49 billion, a PE ratio of 34.30, a P/E/G ratio of 2.42 and a beta of 0.95.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, April 21st. The conglomerate reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The business had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the previous year, the company earned $1.88 earnings per share. The business's revenue for the quarter was up 3.7% on a year-over-year basis. Danaher has set its FY 2026 guidance at 8.350-8.550 EPS. Sell-side analysts forecast that Danaher Corporation will post 8.43 EPS for the current fiscal year.

Danaher Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 24th. Investors of record on Friday, March 27th were paid a $0.40 dividend. This is a boost from Danaher's previous quarterly dividend of $0.32. The ex-dividend date was Friday, March 27th. This represents a $1.60 dividend on an annualized basis and a yield of 0.9%. Danaher's dividend payout ratio (DPR) is 30.95%.

Wall Street Analyst Weigh In

A number of research analysts recently commented on DHR shares. TD Cowen lowered their price target on shares of Danaher from $245.00 to $240.00 and set a "buy" rating for the company in a report on Wednesday. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Danaher in a research report on Friday, March 27th. Leerink Partners raised their target price on shares of Danaher from $260.00 to $270.00 and gave the stock an "outperform" rating in a research report on Friday, January 16th. Morgan Stanley reduced their target price on shares of Danaher from $270.00 to $255.00 and set an "overweight" rating on the stock in a research report on Wednesday. Finally, Argus set a $265.00 target price on shares of Danaher in a research report on Wednesday, January 14th. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $242.45.

Check Out Our Latest Research Report on DHR

About Danaher

(Free Report)

Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Read More

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Danaher Right Now?

Before you consider Danaher, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.

While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines